Abu Dhabi’s Department of Health, M42 and AbbVie enter strategic partnership

Betsy Goodfellow | June 20, 2023 | News story | Medical Communications AbbVie, Abu Dhabi, DoH, M42, Oncology, strategic partnership 

Abu Dhabi’s Department of Health (DoH) has signed a Memorandum of Understanding (MoU) with AbbVie and M42 to advance research personalised medicines and genomics in Abu Dhabi, UAE.

The partnership is intended to progress precision medicine for the diagnosis and treatment of multiple myeloma and non-small cell lung cancer (NSCLC), with the DoH aiming to focus on research that could contribute to various policy changes or guideline implementation hoping to enable broader patient access to innovative approaches in care. 

Dr Asma Al Mannaei, executive director of the Research and Innovation Center at the DoH, Abu Dhabi, commented: “It is with no doubt that personalised medicine and genomics hold the transformative potential to reshape the delivery of care and improve outcomes. Abu Dhabi continues to harness the power of these fields to unlock a new era of healthcare where every patient’s journey is guided by their own genetic blueprint, leading to enhanced quality of life and a brighter future for generations to come. We are proud to witness yet another collaboration with prestigious partners in the biopharma industry during our participation at BIO 2023.”

Hassan Sabbah, general manager at AbbVie Gulf & Levant, added: “This partnership aims to advance precision medicine in the diagnosis and treatment to help enable broader patient access in UAE to innovative therapies. Our efforts are progressing to launch several initiatives that support research and clinical trials and develop innovative solutions to deal effectively with local and regional health needs, challenges and burdens.”

Finally, Francesco Redivo, senior director at G42 Healthcare, a M42 company, stated: “I am proud to witness how our vision of realising personalised healthcare is progressing forward as we strengthen our commitments with like-minded pharma businesses like AbbVie who are known to discover and deliver innovative medicines and solutions that enhance people’s lives. Our collaboration will be built on joint efforts to advance precision medicine by harnessing real world evidence capabilities, shaping innovative solutions around access to care and translating scientific advancements into tangible patient benefits by maximising the potential of Emirati Genome Programme.”

Betsy Goodfellow

Related Content


AbbVie’s Aquipta receives MHRA marketing authorisation

AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a …


AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa

AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up …

NHS building

Abbvie psoriatic arthritis drug approved for use in Scotland

Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has …

Latest content